Liganded Thyroid Hormone Receptor Inhibits Phorbol 12-O-Tetradecanoate-13-Acetate-Induced Enhancer Activity via Firefly Luciferase cDNA by Misawa, Hiroko et al.
Liganded Thyroid Hormone Receptor Inhibits Phorbol
12-O-Tetradecanoate-13-Acetate-Induced Enhancer
Activity via Firefly Luciferase cDNA
Hiroko Misawa, Shigekazu Sasaki*, Akio Matsushita, Kenji Ohba, Hiroyuki Iwaki, Hideyuki Matsunaga,
Shingo Suzuki, Keiko Ishizuka, Yutaka Oki, Hirotoshi Nakamura
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
Abstract
Thyroid hormone receptor (TR) belongs to the nuclear hormone receptor (NHR) superfamily and regulates the transcription
of its target genes in a thyroid hormone (T3)-dependent manner. While the detail of transcriptional activation by T3
(positive regulation) has been clarified, the mechanism of T3-dependent repression (negative regulation) remains to be
determined. In addition to naturally occurring negative regulations typically found for the thyrotropin b gene, T3-bound TR
(T3/TR) is known to cause artificial negative regulation in reporter assays with cultured cells. For example, T3/TR inhibits the
transcriptional activity of the reporter plasmids harboring AP-1 site derived from pUC/pBR322-related plasmid (pUC/AP-1).
Artificial negative regulation has also been suggested in the reporter assay with firefly luciferase (FFL) gene. However,
identification of the DNA sequence of the FFL gene using deletion analysis was not performed because negative regulation
was evaluated by measuring the enzymatic activity of FFL protein. Thus, there remains the possibility that the inhibition by
T3 is mediated via a DNA sequence other than FFL cDNA, for instance, pUC/AP-1 site in plasmid backbone. To investigate
the function of FFL cDNA as a transcriptional regulatory sequence, we generated pBL-FFL-CAT5 by ligating FFL cDNA in the
5’ upstream region to heterologous thymidine kinase promoter in pBL-CAT5, a chloramphenicol acetyl transferase (CAT)-
based reporter gene, which lacks pUC/AP-1 site. In kidney-derived CV1 and choriocarcinoma-derived JEG3 cells, pBL-FFL-
CAT5, but not pBL-CAT5, was strongly activated by a protein kinase C activator, phorbol 12-O-tetradecanoate-13-acetate
(TPA). TPA-induced activity of pBL-FFL-CAT5 was negatively regulated by T3/TR. Mutation of nt. 626/640 in FFL cDNA
attenuated the TPA-induced activation and concomitantly abolished the T3-dependent repression. Our data demonstrate
that FFL cDNA sequence mediates the TPA-induced transcriptional activity, which is inhibited by T3/TR.
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Introduction
Thyroid hormone receptor (TR) belongs to the nuclear
hormone receptor (NHR) superfamily. In a T3-dependent
manner, TR not only activates (positive regulation) but also
inhibits (negative regulation) its target genes. In contrast to that for
the positive regulation, the molecular mechanism of the negative
regulation has been elusive [1–4]. The thyrotropin b subunit
(TSHb) gene is a typical gene for which the expression is inhibited
by T3-bound TR (T3/TR). Using deletion study of its promoter, a
short DNA sequence, GGGTCA, immediately downstream of the
transcription start site has been postulated as a negative T3
responsive element (nTRE). However, our detailed analysis in the
presence of the transcription factors Pit1 and GATA2, which are
the determinants of thyrotroph differentiation in pituitary gland
[5], revealed that the reported nTRE is not necessary for T3-
induced inhibition [6]. We proposed that the interference of
GATA2-dependent transactivation by T3/TR is the main
mechanism of negative regulation of the TSHb gene by T3 [6].
In this scenario, T3/TR interacts with GATA2 but not DNA.
This kind of inhibitory mechanism is referred to as ‘‘tethering’’,
where the transactivation function of DNA-binding transcription
factor is suppressed by liganded NHR via protein-protein
interaction [7–9]. For instance, AP-1-induced activity is repressed
by T3/TR [10,11] and liganded glucocorticoid receptor (GR)
[7,10,12], while the activity of NFkB is inhibited by liganded GR
and estrogen receptor (ER) a [9,13,14]. Ligand/receptor specific-
ity was reported in the inhibition via tethering mechanism [6,14]
although direct DNA binding of NHRs is not required.
Unexpectedly, Lopez et al. [10] reported that a sequence,
TGACACA, in pUC series plasmids mimics the function of AP-1
site (pUC/AP-1) and artificially mediates the negative regulation
by T3/TR in Hela cells. pUC/AP-1 is included in the sequence,
nt. 1/138, in pUC18/19 vector [15]. Because of the high yield in
E. coli culture, pUC plasmid-derived backbone has been preferred
in many plasmid constructions. pUC/AP-1 sequence is also found
in pBR322 [16], which was the most common plasmid used for
DNA cloning in the early period of molecular biology. pUC and
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have been widely used as parts of so-called ‘‘homemade plasmids’’
as well as commercial plasmids, including some pGEM series
(Promega, WI, U.S.A.). More than 2000 plasmid constructs
bearing the sequence identical to nt. 1/138 in pUC18/19 vector
were detected in the BLAST database. pUC- or pBR322-derived
plasmid backbone was also utilized in the construction of reporter
genes for the study of the negative regulation of the TSHb gene by
T3/TR [17–19].
Besides the negative regulation via pUC/AP-1 site, it was
suggested that T3/TR may artificially suppress the activity of
firefly luciferase (FFL)-based reporter genes driven by thymidine
kinase (TK) promoter [20–22] or O-tet-CMV promoter [23].
These studies indicated artificial negative regulation via FFL
cDNA in various cell lines. However, deletion analysis of FFL
cDNA for the identification of the responsible sequence was not
conducted since the negative regulation was evaluated by
measuring the FFL enzymatic activity [20–23]. Thus, there
remains the possibility that inhibition by T3 is mediated via a
DNA sequence other than FFL cDNA in plasmid backbone, for
example, pUC/AP-1 site.
It is noteworthy that artificial repression by T3/TR was not
detected for chloramphenicol acetyl transferase (CAT)-based
reporter gene in CV1 [20] and JEG3 cells [22], suggesting that
CAT cDNA is safe, at least in these cell lines. We decided to
investigate the function of FFL cDNA as a transcription regulatory
sequence using CAT-based reporter gene. We generated pBL-
FFL-CAT5 by fusing FFL cDNA to the upstream flanking region
of the TK promoter in a CAT-based reporter plasmid, pBL-CAT5
[24], which lacks pUC/AP-1 site [10]. We found that FFL cDNA
contains the sequence that is strongly activated by a protein kinase
C activator, phorbol 12-O-tetradecanoate-13-acetate (TPA), in
CV1 and JEG3 cells and that this activity is repressed by T3/TR.
Current results support the previous reports that FFL cDNA
mediates the artificial negative regulation by T3 [20,22,23].
Materials and Methods
Plasmid construction
To isolate the DNA fragment containing the FFL coding region,
the sequence GGATCT (nt. 1891/1896) at the 39 flanking region
of FFL cDNA in pGL2-basic vector (Promega, Madison, WI,
U.S.A.) was mutated to the BamHI site (GGATCC) using a site-
directed mutagenesis kit (Stratagene, La Jolla, CA, U.S.A.). This
mutant plasmid was digested with HindIII and BamHI, and the
1750 bp DNA fragment was separated in gel electrophoresis and
was ligated in the HindIII-BamHI site in the multi-cloning site in
pBL-CAT5 [24] (Fig. 1A). Using the site-directed mutagenesis kit
(Stratagene, U.S.A.), the positive TRE (pTRE)-like sequence
(AGGTGA-CGCG-TGTGGCC) in the thymidine kinase (TK)
promoter [25] of pBL-FFL-CAT5 was mutated to generate pBL-
FFL-CAT5-mtk. Deletion mutants of pBL-FFL-CAT5 were
generated using PCR and standard molecular biology techniques.
The sequence between nt. 626/640 in FFL cDNA was mutated
using the site-directed mutagenesis kit to generate the constructs,
MA, MB, MC, and MD. The coding regions for hRluc and Luc2
were excised with HindIII and XbaI from phRL-null vector and
pGL4.10 [luc2] vector (Promega), respectively. These DNA
fragments were subcloned into the HindIII-XbaI sequence of
pBL-CAT5 to create pBL-hRluc-CAT5 and pBL-Luc2-CAT5. All
plasmid constructs were confirmed by sequencing. The expression
plasmids for human TRb1 (pCMX-hTRb1), estrogen receptor a
(pSG5-hERa), vitamin D3 receptor (pSG5-hVDR), retinoic acid
receptor (RAR) a (pCMX-hRARa), and glucocorticoid receptor
(GR) (pCMX-hGR) were as described previously [26,27].
Cell culture and transient transfection
A monkey kidney cell line, CV1 [28], and a human embryonic
kidney cell line, 293T [29], were grown in monolayer culture at
37C under 5% CO2/95% air in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal calf serum, penicillin G
(100 units/ml), and streptomycin (100 mg/ml). CV1 and 293T
cells were trypsinized and plated in 60-mm dishes for 24 h before
transient transfection using the calcium-phosphate technique [30].
Cells at a density of 10
6 cells/plate were transfected with 0.4 mgo f
TR expression vector (pCMX-hTRb1) along with 1.0 mg of pBL-
FFL-CAT5, 1.8 mgo fb-galactosidase expression vector pCH111
(a modified version of pCH110; Pharmacia LKB Biotechnology,
Piscataway, NJ, U.S.A.), and pCMX empty vector as carrier DNA
(to adjust the total to 5.2 mg of DNA/dish). After the cells were
exposed to the calcium phosphate/DNA precipitates for 20 h, the
medium was replaced with fresh DMEM containing 5% fetal calf
serum depleted of thyroid hormones or the same medium was
supplemented with 100 ng/ml phorbol 12-O-tetradecanoate-13-
acetate (TPA) and/or 1 mM T3. After incubation for an additional
24 h, the cells were harvested and the CAT activity was measured
and normalized by the b-galactosidase activity as described
previously. JEG3 cells [31] were cultured in OptiMEM-1 medium
(BRL-Gibco, Grand Island, NY, USA) containing 2% fetal calf
serum, penicillin G (100 units/ml), and streptomycin (100 mg/ml).
The cells were trypsinized 12–18 h before transfection and plated
into medium containing 2% T3-stripped fetal calf serum. The cells
were transfected with 1 mg of pBL-FFL-CAT5, 1.8 mg of pCH111,
0.4 mg of pCMX-hTRb1, and pCMX empty vector as carrier
DNA to adjust the total to 5.2 mg of DNA/dish [32]. After 4 h of
exposure to calcium phosphate/DNA precipitates, the cells were
cultured in medium with 1 mM T3 and/or 100 ng/ml TPA for
36–48 h and the CAT and b-galactosidase activities were
measured. In CAT reporter assay, we also performed transfection
with CMV (cytomegalovirus)-CAT (10 ng/dish), the magnitude of
which was adjusted to 100%.
Gel shift assay
FFL14 probe (sense: 59-CCTAAGGGTGTGGCCCTTCCG-
CATAGAACTGCCTGCGTCA-39 and antisense: 59-TGACG-
CAGGCAGTTCTATGCGGAAGGGCCACACCCTTAGG-39)
and consensus AP-1 probes (sense: 59-TCGACGGTATCGA-
TAAGCTATGACTCATCCGGGGGATC-39 and antisense: 59-
GATCCCCCGGATGAGTCATAGCTTATCGATACCGTC-
GA-39) were annealed and labeled with c-
32P-ATP using T4
polynucleotide kinase (Toyobo, Tokyo, Japan). CV1 nuclear
extracts (CV1-NE) were prepared as described previously [33].
The c-
32P-labeled probes and 2 mg of CV1-NE were incubated for
30 min on ice in 20 ml of binding buffer containing 20 mM Hepes-
NaOH (pH 7.9), 50 mM KCl, 0.05 mM EDTA, 2.5 mM MgCl2,
8.5% glycerol, 1 mM dithiothreitol, and 0.5 mg/ml poly(dI-dC).
For the supershift assays, anti-cJun antibody (no. sc-1694x, Santa
Cruz Biotechnology, CA) was added to the binding reaction
mixture. DNA-protein complexes were resolved by electrophoresis
on a 5% polyacrylamide gel at 150 V for 120 min at room
temperature. For the competition assay, 100-fold excess of cold
FFL14G was added. The gel was dried and labeled bands were
visualized using the BAS-1000 autoradiography system (Fuji Film,
Tokyo, Japan).
Luciferase Gene Mediates T3-Induced Inhibition
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FFL cDNA contains the sequence that is activated by TPA
Because it was reported that CAT-based reporter genes do not
mediate the repressive effect by T3/TR [20,22], we selected CAT
reporter system to study whether FFL cDNA possesses the
sequence mediating the inhibition by T3/TR. A CAT reporter
gene, pBL-CAT5 plasmid (Fig. 1A), was utilized because reported
pUC/AP-1 site, TGACACA, was deleted [24]. Moreover, in pBL-
CAT5, two poly-A signals of SV40 large T encoding gene were
inserted into the 59 region of the multi-cloning sites to abrogate the
influence of upstream signal. We ligated the FFL cDNA in the
pBL-CAT5, creating pBL-FFL-CAT5 (Fig. 1A). We employed a
monkey kidney-derived cell line, CV1 [28], because it has been
widely used in the study of T3-dependent positive and negative
regulations [6,20,26,34–37]. On the basis of the speculation that
FFL cDNA may contain the sequence responsive to PKC signaling
as in the case of pUC/AP-1 site [10], we tested the effect of TPA
on the activity of FFL cDNA fused with TK promoter. As shown
in Fig. 1B, pBL-FFL-CAT5 was robustly stimulated by TPA
treatment while moderately activated by co-transfection of Jun and
Fos. The transactivation of pBL-FFL-CAT5 by TPA occurred in a
dose-dependent fashion (Fig. 1C). In contrast, pBL-CAT5 was not
activated by co-transfection of Jun and Fos or TPA treatment
(Fig. 1B), suggesting that pBL-CAT5 does not have the cryptic
sequence that mimics AP-1.
Figure 1. FFL cDNA functions as the TPA-induced enhancer in CV1 cells. A. Structure of pBL-FFL-CAT5. FFL cDNA was inserted into the
HindIII-BamHI site in pBL-CAT5 (4.40 kb). For pBL-CAT5 construction, AatII-HindIII fragment of pBL-CAT2 [69] that contains pUC/AP-1 site was deleted
and substituted by two fragments from SV40-poly-adenylation signals (poly-A) [24]. B. pBL-FFL-CAT5 but not pBL-CAT5 (mother plasmid) was
strongly stimulated by TPA while activation by co-transfection of Jun and Fos was moderate. CV1 cells were transfected with 1.0 mg of the pBL-FFL-
CAT5 with or without the expression vector for Jun and Fos (0.2 mg each). After incubation for 24 h in the presence or absence of 100 ng/ml TPA, CAT
activity was measured with normalization of the transfection efficiency by b-galactosidase activity. The results are the means +/2 SD from three
independent experiments. *, P,0.05. #, the statistical significance (P,0.05) of TPA(2) vs. TPA(+). C. Transcriptional activity of pBL-FFL-CAT5
stimulated in a TPA dose-dependent manner. CV1 cells were transfected with 1.0 mg of the pBL-FFL-CAT5 in the presence of TPA (0–1000 ng/ml). The
results are the means +/2 SD from three independent experiments. *, P,0.05.
doi:10.1371/journal.pone.0028916.g001
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suppressed by T3/TR
As shown in Fig. 2A and B, TPA-induced transactivation of
pBL-FFL-CAT5 was repressed by T3/TR. We examined the
effect of other liganded NHRs on the TPA-dependent transcrip-
tional activity of pBL-FFL-CAT5 (data not shown). There was no
significant effect on the TPA-induced transcriptional activity by
liganded-ERa, vitamin D3 receptor, and retinoic acid receptor a.
Thus, there is receptor/ligand-specificity in the FFL cDNA-
mediated inhibition. Unexpectedly, this activity was not repressed
by the liganded GR, suggesting that the transcription factor
mediating TPA signal may not be Jun/Fos [7,10,12]. Human
choriocarcinoma cell line, JEG3 [31], has been utilized for the
analysis of T3-dependent negative regulation [32,38–45]. In this
Figure 2. T3/TR inhibits the transcriptional activity of FFL cDNA stimulated by TPA in CV1 and JEG3 but not 293T cells. A. T3/TR
inhibits the transcriptional activity of pBL-FFL-CAT5 but not pBL-CAT5 stimulated by TPA in CV1 cells. TRb1 expression vector (0.4 mg) was transfected
into CV1 cells along with 1.0 mg of the pBL-FFL-CAT5 or pBL-CAT5. After incubation for 24 h in the presence or absence of 100 ng/ml TPA and/or
1 mM T3, CAT activity was measured with normalization of the transfection efficiency by b-galactosidase activity. The results are the means +/2 SD
from four independent experiments. *, P,0.05. #, the statistical significance (P,0.05) of TPA(2) vs. TPA(+). B. T3 dose dependence in the inhibition
of pBL-FFL-CAT5 activated by TPA. pBL-FFL-CAT5 was transfected into CV1 cells in the presence of 100 ng/ml TPA and 0–100 nM T3. C. T3/TR
inhibited the transcriptional activity of pBL-FFL-CAT5, but not pBL-CAT5, stimulated by TPA in JEG3 cells. TRb1 expression vector (0.4 mg) was
transfected into JEG3 cells along with 1.0 mg of pBL-FFL-CAT5 or pBL-CAT5 in the presence or absence of 100 ng/ml TPA and/or 1 mM T3. The results
are the means +/2 SD from four independent experiments. *, P,0.05. D. Enhancer activity of FFL cDNA is not activated by TPA or inhibited by T3/TR
in 293T cells. TRb1 expression vector (0.4 mg) was transfected into 293T cells along with 1.0 mg of pBL-FFL-CAT5 or pBL-CAT5. After incubation for
24 h in the presence or absence of 100 ng/ml TPA and/or 1 mM T3, CAT activity was measured with normalization of the transfection efficiency by
b-galactosidase activity. The results are the means +/2 SD from three independent experiments. *, P,0.05.
doi:10.1371/journal.pone.0028916.g002
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by T3/TR (Fig. 2C). In contrast, no TPA-induced activation or
negative regulation by T3/TR was detected in human embryonic
kidney-derived 293T cells [29] (Fig. 2D), indicating that this cell
line lacks the transcription factor conducting TPA signal to FFL
cDNA sequence.
Reported half-site-like sequences in the TK promoter are
not involved in the negative regulation of the TPA-
induced activation by T3
In the positive regulation, TR heterodimerizes with retinoid X
receptor on positive T3-responsive element (pTRE), which consists
of a direct repeat of half-sites (typically, AGGTCA) with 4 random
spacing nucleotides (direct repeat 4, DR4) [34]. Tillman et al. [20]
and Maia et al. [22] suggested the possibility that, when strong
pTRE exists in the promoter, T3-induced activation may mask the
inhibitory effect by T3 on the transcriptional activity via FFL
cDNA. According to Park et al. [25], the thymidine kinase (TK)
promoter contains a pTRE-like sequence (nt. -22/-2, AGGTGA-
CGCGTG-TGGCCT, Fig. 3A), which may confer T3-dependent
activation in COS [46], GC [47], and GH4C1 cells [25].
However, as shown in Fig. 2A (lanes 3 and 5), T3/TR did not
activate this promoter in pBL-CAT5 in CV1 cells. To exclude
another possibility that one of these half-site-like sequences
functions as nTRE, we generated pLB-FFL-CAT5-mtk, in which
the DNA sequences of both half-sites were mutated (Fig. 3A). As
shown in Fig. 3B, both TPA-induced activation and inhibition by
T3/TR were maintained. These results indicated that the reported
pTRE or the half-site-like sequences in the TK promoter do not
affect the T3/TR-dependent negative regulation in CV1 cells.
FFL cDNA contains the sequence that mediates
TPA-induced activation
nTRE was defined as the sequence where unliganded TR may
function as a transcriptional activator [17]. However, the existence
of nTRE is unlikely because unliganded TR alone did not activate
pBL-FFL-CAT5 in CV1 cells (Fig. 2A, lanes 2 and 4). We
speculated on the involvement of a tethering mechanism [7–9],
where activity of TPA-dependent transcription factor is inhibited by
T3/TR. We carried out deletion analysis of the FFL cDNA (Fig. 4,
left panel). As shown in Fig. 4 (middle panel), the deletion of nt. 1/
530 increased the basal and the TPA-induced activities while
truncations of nt. 531/613 and nt. 614/640 reduced them. These
results suggest the existence of the inhibitory sequence(s) in nt. 1/
530 and at least two activation sequences in nt. 531/613 and nt.
614/640. The finding that TPA treatment modestly but signifi-
cantlypotentiatedthetranscriptionoftheD640constructssuggested
the existenceof theweak TPA-responsiveelement(s)in the sequence
downstream ofnt.640. Interestingly,negativeregulationbyT3/TR
was blunted in the D640 construct (Fig. 4, right panel). These results
suggest that the DNA sequence between nt. 613/640 may include
the sequence responsible for the inhibition by T3/TR.
The CV1-derived nuclear protein that recognizes the DNA
sequence between nt. 626/640 is not AP-1
Using nuclear extract from CV1 cells (CV1-NE), we performed
gel shift assay with
32P-labeled DNA probes encompassing various
regions between nt. 613/640. The sequence between nt. 626/640
has weak homology with consensus AP-1 site (Fig. 5A). We found
the specific binding signal at nt. 626/640 (Fig. 5B) that was
competed with by the 100-fold molar excess of the cold specific
competitor, but not its mutant (FFL14G) (Fig. 5B). As a control
experiment, we performed gel shift assay using CV1-NE and
32P-
labeled consensus AP-1 site (Fig. 5A). As shown in Fig. 5C, we
detected the binding signal with consensus AP-1 site. This signal
was specifically abolished by the 100-fold molar excess of the cold
specific competitor and eliminated by anti-cJun antibody. These
results indicated the existence of endogenous cJun in CV1 cells.
However, as shown in Fig. 5D, the binding signal with FFL14 was
not affected by the addition of anti-cJun antibody, suggesting that
AP-1 is not the nuclear protein recognizing the sequence between
nt. 626/640 in CV1 cells.
The DNA sequence between nt. 626/640 in FFL cDNA
mediates both TPA-induced activity and negative
regulation by T3/TR
On the basis of the results of the gel shift assay in Fig. 5, we
generated the scanning mutations between nt. 626/640 (Fig. 6A).
As shown in Fig. 6B (left panel), the basal transcriptional activities
without TPA were increased in these mutants, suggesting that the
Figure 3. TPA-induced activation or the negative regulation by
T3 was not affected by the reported pTRE (half-site-like
sequences) in the TK promoter. A. Schematic representation of
pBL-FFL-CAT5 (WT) and its mutant, pBL-FFL-CAT5-mtk. The nucleotides
in both half-sites (arrows) in the reported palindromic TRE in TK
promoter [25] were mutated in pBL-FFL-CAT5-mtk (boldface). B. The
mutation of reported pTRE does not affect the TPA-induced transcrip-
tional activity or the repression by T3/TR. In the presence or absence of
TPA (100 ng/ml) and or T3 (1 mM), pBL-FFL-CAT5 (WT) or pBL-FFL-CAT5-
mtk was transfected into CV1 cells with or without TRb1 expression
plasmid. CAT activity was measured with normalization of the
transfection efficiency by the b-galactosidase activity. The results are
the means +/2 SD from three independent experiments. *, P,0.05.
doi:10.1371/journal.pone.0028916.g003
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that TPA-induced stimulation evaluated by fold activation was
significantly reduced in the mutant MA (Fig. 6B, right panel). The
activity of the putative TPA-response sequence(s) downstream of
nt. 640 was thought to be masked in this mutant (Fig. 6B and C)
presumably because it is very weak (Fig. 4, middle panel).
Importantly, the repression by T3/TR was not detected in MA
(Fig. 6C), suggesting that the DNA sequence between nt. 626/640
mediates not only the TPA-dependent activation but also the
artificial negative regulation by T3/TR.
cDNAs of modified luciferase, hRluc, and Luc2 do not
mediate TPA-induced activation or negative regulation
by T3/TR in CV1 cells
The sequence homology between FFL and modified Renilla
reniformis-derived luciferase (hRluc) [48] is low (9.8% at amino
acid level, 8.4% at DNA level) and there is no sequence in hRluc-
cDNA similar to nt. 613/640 of FFL-cDNA. To confirm that
hRluc cDNA does not respond to TPA stimulation, we fused
hRluc cDNA to the pBL-CAT5, generating pBL-hRluc-CAT5
(Fig. 7A). pBL-hRluc-CAT5 was not activated by TPA or Jun/Fos
co-expression in CV1 cells (Fig. 7B) and its activity was not
affected by T3/TR (Fig. 7C). To eliminate the artificial
transactivation mediated by the sequence of cDNA of FFL
[49,50] or Luc+ [51], modified luciferase, Luc2, was also
developed [51]. For the evaluation of Luc2 cDNA, we generated
pBL-Luc2-CAT5, in which Luc2 cDNA was ligated in pBL-CAT5
(Fig. 7A). Again, pBL-Luc2-CAT5 was not activated by TPA or
suppressed by T3/TR (Fig. 7C).
Discussion
In this study, we confirmed the existence of the sequence in FFL
cDNA that mediates artificial negative regulation by T3/TR. FFL
assay has many advantages compared with CAT assay [52,53].
First, FFL assay is more sensitive and has broader linearity than
CAT assay. Second, no radioactivity is required and the assay
procedure is very quick and safe. Finally, FFL assay is more
appropriate for kinetic study than CAT assay because, in
mammalian cells, the half-life of FFL protein is much shorter
(approx. 3 hours) than that of CAT protein (approx. 50 hours). By
virtue of these advantages, FFL-based reporter assays have been
utilized in numerous studies for transcriptional regulation. For
example, when PubMed database was searched with the keywords
of ‘‘phorbol’’ and ‘‘luciferase’’, 836 publications were retrieved (in
April, 2011). FFL-based reporter assays were also employed in
studies of T3-induced negative regulation [35–37,40,43,54–59].
However, we demonstrated here that, in CV1 [28] and JEG3 cells
[31], the FFL cDNA functions as TPA-induced enhancer (Fig. 1B
and C) and its activity is inhibited by T3/TR (Fig. 2A, B and C).
There are at least two activation sequences in FFL cDNA. One is
located downstream of nt. 640 (Fig. 4) and another is between nt.
626/640 (Fig. 6C). The latter may be an inhibitory sequence
because transcriptional activity was increased by its mutation
(Fig. 6B, left panel) and this inhibition was relieved by the TPA
treatment (Fig. 6C). The TPA-responsive sequence downstream of
nt. 640 appears to be much weaker than that at nt. 626/640. In
agreement with the findings in Fig. 4 (right panel), the results in
Fig. 6C (right panel) suggest that the sequence between nt. 626/
640 (Fig. 4) also mediates the negative regulation by T3/TR in
CV1 cells. We speculate that the negative regulation via FFL
cDNA is mediated by a tethering mechanism [7–9], but not so-
called nTRE [17]. First, when the sequence nt. 626/640 was
mutated (Fig. 6A), the negative regulation of FFL cDNA was
abolished concomitantly with TPA-induced activity (Fig. 6C).
Second, there is no sequence between nt. 626/640 that has
homology with half-site. Third, although nTRE was previously
defined as the DNA sequence on which unliganded TR may
function as a transcriptional activator [17], the current results rule
out the presence of this kind of DNA sequence in FFL cDNA
(Fig. 2A, lanes 2 and 4). Finally, because CV1 cells do not have
endogenous TR [34], the protein that binds with the sequence
between nt. 626/640 (Fig. 5B and D) should not be TR.
Although one may argue that, in experimental conditions
without PKC activity or Jun/Fos, FFL-based reporter assay can be
utilized for the study of negative regulation, at least 11 different
PKC subtypes have been reported and some of them are expressed
ubiquitously [60]. Moreover, PKC activates multiple transcription
factors besides Jun/Fos. For example, the major transcription
factor that mediates TPA signal via FFL cDNA in CV1 cells is not
Jun/Fos (Fig. 5). The length of FFL cDNA (1653 bp) is much
longer than that of CAT gene (657 bp). Computer search predicts
more than 250 potential sites for DNA binding transcription
factors in FFL cDNA [50]. The cDNAs of modified luciferase,
Luc+ [51,61], and conventional Renilla luciferase [48,62,63] also
harbor numerous short sequences that can be recognized by a
variety of transcription factors. It may be useful to search known
binding sites in the reporter gene [50]. We also recommend
computer search for pUC/AP-1 site (TGACACA) [10]. However,
the information of the full-length sequence is not always available
in ‘‘home-made plasmids’’. Involvement of a transcription factor is
usually difficult to predict owing to redundancies of the
transcription factor binding sites. Modified luciferase genes
including hRluc [48] and Luc2 [51] may be safer than FFL
(Fig. 7B and C) presumably because the majority of predicted
transcription factor binding sites were mutated. To verify the effect
of various stimulations or chemical compounds in different cell
Figure 4. Deletion analysis of FFL cDNA as a transcriptional
regulatory sequence. Schematic representation of deletion mutants
of pBL-FFL-CAT5 is illustrated in the left panel. Fold repression (right
panel) was calculated from CAT activity without T3 divided by that with
T3. In the deletion mutant D640, basal activity was reduced. Although
TPA treatment modestly but significantly potentiated the promoter
activity, repression by T3/TR was blunted (middle and right panels). CAT
activity was measured with normalization of the transfection efficiency
by b-galactosidase activity. The results are the means +/2 SD from
three independent experiments. *, P,0.05.
doi:10.1371/journal.pone.0028916.g004
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may be informative.
Although the artificial negative regulation by FFL cDNA or
pUC/AP-1 site can be neglected when the promoter/enhancer
activity is much stronger than that of these sequences [20], it
should be kept in mind that deletion or mutation analyses of
promoters often decrease their transcriptional activities. Once the
activity of the deleted promoter becomes less than that of FFL
cDNA or pUC/AP-1, the reporter signal may be artificially
maintained by these sequences, which can be reduced by T3/TR.
Madison et al. [40] performed deletion analysis of the a-
glycoprotein subunit (GSU) promoter in JEG3 cells to identify
its nTRE. Their FFL assay showed that negative regulation by
T3/TR was maintained even in the minimal promoter containing
only TATA box (nt. 235). There is the possibility that the activity
of FFL cDNA surpassed that of minimal aGSU promoter (TATA
box) and caused artificial negative regulation. A similar problem
was suggested in a study that attempted to define the structure of
nTRE. Using an FFL-based reporter gene, Na ¨a ¨r et al. [35]
reported that deletion of spacing nucleotides of DR4-type TRE
converted T3/TR from transcriptional activator to repressor and
proposed that unspaced direct repeat (DR0) might be an nTRE.
However, their observation was not reproduced with a CAT-based
construct (private communication from Kazuhiko Umesono).
Tillman et al. [20] speculated that FFL cDNA-mediated negative
regulation might be regenerated after the disruption of DR4-type
pTRE by deleting spacing nucleotides.
Negative regulation has been regarded as the mirror image of
positive regulation and unliganded TR was postulated to be a
transcriptional activator. On the basis of this hypothesis, deletion
analysis of the TSHb gene was performed in the absence of T3
and the putative nTRE was reported [17]. Unexpectedly,
Figure 5. The CV1-derived nuclear protein that recognizes the DNA sequence between nt. 626/640 is not AP-1. A. Sense sequence of
FFL14 oligo DNA probe encompassing nt. 613/652, its mutant (FFL14G), and AP-1 oligo DNA probe [70]. The sequence that has weak homology with
AP-1 site in FFL14 oligo and consensus Jun/Fos binding sequence in AP-1 are indicated in boldface. FFL14G that has mutations in the sequence
similar to AP-1 site was used as control for competition assay. B. Gel shift assay using radiolabeled FFL14 with CV1 nuclear extract (CV1-NE). Arrow
indicates the specific binding. C. Gel shift assay using radiolabeled AP-1 probe [70] with CV1-NE. Arrowhead indicates the specific binding containing
cJun. The binding signal was abolished by the addition of anti-cJun antibody (lanes 5 and 6). D. Gel shift assay using radiolabeled FFL14 probe with
CV1-NE in the presence of anti-cJun antibody. The binding signal (arrow) was not affected by the addition of anti-cJun antibody (lanes 5–7). NS, non-
specific cold competitor.
doi:10.1371/journal.pone.0028916.g005
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This finding suggests that unliganded TR per se is not necessary
for the transcription of the TSHb gene and that another
transcription factor maintains the basal transcriptional activity
before inhibition by T3. Indeed, transcriptional activity by
unliganded TR was extremely low and almost negligible compared
with that driven by Pit1 and GATA2 [6,26], which are the
essential activators of the TSHb gene [5,33]. Using CAT-based
reporter gene lacking the pUC/AP-1 site, we carried out deletion
analysis of the TSHb promoter under the co-expression of
GATA2 and Pit1. We found that the reported nTRE is not
required for negative regulation by T3 [6]. We proposed a model
in which the mechanism for the T3-dependent inhibition is
mediated by the tethering of T3/TR with GATA2 [6]. Although
the genes for aGSU, prepro-thyrotropin releasing hormone, and
myosin heavy chain b are also inhibited by T3/TR and putative
nTREs have been postulated in these genes, unliganded TRs may
not be a transcriptional activator because their expression levels
were not reduced in TR-null mice [57,64–67].
Because the majority of previous studies paid little attention to
the artificial inhibition by T3/TR via FFL cDNA or pUC/AP-1
site, there has remained the possibility that the transcriptional
activity via FFL cDNA or pUC/AP-1 site might be regarded as
that by unliganded TR. Current data combined with our previous
reports [6,26] suggest that the characterization of the mechanism
for the basal transcriptional activity before T3 addition as well as
Figure 6. The sequence between nt. 626/640 mediates both TPA-dependent activation and the negative regulation by T3/TR. A.
Schematic representation of pBL-FFL-CAT5 (WT) and its mutants, MA, MB, MC, and MD. B. The stimulatory effect by TPA is decreased in MA. In the
presence or absence of TPA (100 ng/ml), pBL-FFL-CAT5 (WT) or its mutants (MA-D) were transfected into CV1 cells. CAT activity was measured with
normalization of the transfection efficiency by the b-galactosidase activity (left panel). Fold activation (right panel) was calculated from CAT activity
with TPA divided by that without TPA. C. The sequence between nt. 626/640 in the FFL cDNA mediates both TPA-dependent activation and negative
regulation by T3/TR. In the presence or absence of TPA (100 ng/ml) and/or T3 (1 mM), pBL-FFL-CAT5 (WT) or its mutant, MA, was transfected into CV1
cells with or without TRb1 expression plasmid. CAT activity was measured with normalization of the transfection efficiency by the b-galactosidase
activity. The results are the means +/2 SD from three independent experiments. *, P,0.05.
doi:10.1371/journal.pone.0028916.g006
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assay has broad linearity, careful interpretation and appropriate
control are necessary when the promoter activity before T3
addition decreases in the course of deletion analysis. Information
on the factor required for the basal promoter activity is helpful to
avoid the artificial negative regulation via the sequence in plasmid
backbone. A strategy to study the negative regulation by T3/TR
should be established in future [1–4] because approximately 20–
50% of T3-sensitive genes are negatively regulated by T3/TR in
vivo [4,68] and it may also provide insight into the mechanism of
ligand-dependent negative regulation by other NHRs.
Acknowledgments
We are grateful to the following researchers for providing the plasmids: Drs.
Kazuhiko Umesono (Kyoto University, Japan), Ronald M. Evans (The Salk
Institute, La Jolla, USA), Bruno Lucow (German Cancer Research Center,
German), and Akira Kakizuka (Kyoto University, Kyoto, Japan).
Author Contributions
Conceived and designed the experiments: H. Misawa S. Sasaki HN.
Performed the experiments: H. Misawa KI. Analyzed the data: H. Misawa
S. Sasaki HN KO HI. Contributed reagents/materials/analysis tools: H.
Misawa S. Sasaki AM H. Matsunaga S. Suzuki. Wrote the paper: H.
Misawa S. Sasaki HN. Obtained permission for use of cell line: YO.
References
1. Shupnik MA (2000) Thyroid hormone suppression of pituitary hormone gene
expression. Rev Endocr Metab Disord 1: 35–42.
2. Eckey M, Moehren U, Baniahmad A (2003) Gene silencing by the thyroid
hormone receptor. Mol Cell Endocrinol 213: 13–22.
Figure 7. cDNAs of modified luciferase, hRluc and Luc2, do not mediate TPA-induced activation or negative regulation by T3/TR in
CV1 cells. A. Schematic representation of pBL-FFL-, pBL-hRluc-, and pBL-Luc2-CAT5. The cDNA of FFL, hRluc, or Luc2 was subcloned into the multi-
cloning site of pBL-CAT5, which lacks pUC/AP-1 site. B. Co-transfection of Jun/Fos and/or treatment of TPA potentiated the enhancer activity of FFL
cDNA, but not hRluc cDNA. pBL-FFL-CAT5 or pBL-hRluc-CAT5 (1.0 mg) was transfected into CV1 cells with or without the expression plasmids for Jun
and Fos (0.2 mg each). After incubation for 24 h in the presence or absence of 100 ng/ml TPA, CAT activity was measured with normalization of the
transfection efficiency by b-galactosidase activity. The results are the means +/2 SD from three independent experiments. *, P,0.05. C. The cDNAs of
hRluc [48] and Luc2 [51] do not function as TPA-induced enhancers and are not affected by T3/TR. TRb1 expression vector (0.4 mg) was transfected
into CV1 cells along with 1.0 mg of the pBL-FFL-, pBL-hRluc-, or pBL-Luc2-CAT5. After incubation for 24 h in the presence or absence of 100 ng/ml
TPA and/or 1 mM T3, CAT activity was measured with normalization of the transfection efficiency by b-galactosidase activity. The results are the
means +/2 SD from three independent experiments. *, P,0.05.
doi:10.1371/journal.pone.0028916.g007
Luciferase Gene Mediates T3-Induced Inhibition
PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e289163. Lazar MA (2003) Thyroid hormone action: a binding contract. J Clin Invest 112:
497–9.
4. Weitzel JM (2008) To bind or not to bind - how to down-regulate target genes by
liganded thyroid hormone receptor? Thyroid Res 1: 4.
5. Dasen JS, O’Connell SM, Flynn SE, Treier M, Gleiberman AS, et al. (1999)
Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced
determination of pituitary cell types. Cell 97: 587–98.
6. Matsushita A, Sasaki S, Kashiwabara Y, Nagayama K, Ohba K, et al. (2007)
Essential role of GATA2 in the negative regulation of thyrotropin b gene by
thyroid hormone and its receptors. Mol Endocrinol 21: 865–84.
7. Pfahl M (1993) Nuclear receptor/AP-1 interaction. Endocr Rev 14: 651–8.
8. Herrlich P (2001) Cross-talk between glucocorticoid receptor and AP-1.
Oncogene 20: 2465–75.
9. De Bosscher K, Vanden Berghe W, Haegeman G (2003) The interplay between
the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1:
molecular mechanisms for gene repression. Endocr Rev 24: 488–522.
10. Lopez G, Schaufele F, Webb P, Holloway JM, Baxter JD, et al. (1993) Positive
and negative modulation of Jun action by thyroid hormone receptor at a unique
AP1 site. Mol Cell Biol 13: 3042–9.
11. Pernasetti F, Caccavelli L, Van de Weerdt C, Martial JA, Muller M (1997)
Thyroid hormone inhibits the human prolactin gene promoter by interfering
with activating protein-1 and estrogen stimulations. Mol Endocrinol 11: 986–96.
12. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, et al. (1994) A distinct
modulating domain in glucocorticoid receptor monomers in the repression of
activity of the transcription factor AP-1. Embo J 13: 4087–95.
13. Stein B, Yang MX (1995) Repression of the interleukin-6 promoter by estrogen
receptor is mediated by NF-kappa B and C/EBPb. Mol Cell Biol 15: 4971–9.
14. Liden J, Delaunay F, Rafter I, Gustafsson J, Okret S (1997) A new function for
the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA
transactivation. J Biol Chem 272: 21467–72.
15. Yanisch-Perron C, Vieira J, Messing J (1985) Improved M13 phage cloning
vectors and host strains: nucleotide sequences of the M13mp18 and pUC19
vectors. Gene 33: 103–19.
16. Balbas P, Soberon X, Bolivar F, Rodriguez RL (1988) The plasmid, pBR322.
Biotechnology 10: 5–41.
17. Wondisford FE, Farr EA, Radovick S, Steinfelder HJ, Moates JM, et al. (1989)
Thyroid hormone inhibition of human thyrotropin b-subunit gene expression is
mediated by a cis-acting element located in the first exon. J Biol Chem 264:
14601–4.
18. Carr FE, Kaseem LL, Wong NC (1992) Thyroid hormone inhibits thyrotropin
gene expression via a position-independent negative L-triiodothyronine-
responsive element. J Biol Chem 267: 18689–94.
19. Hallenbeck PL, Phyillaier M, Nikodem VM (1993) Divergent effects of 9-cis-
retinoic acid receptor on positive and negative thyroid hormone receptor-
dependent gene expression. J Biol Chem 268: 3825–8.
20. Tillman JB, Crone DE, Kim HS, Sprung CN, Spindler SR (1993) Promoter
independent down-regulation of the firefly luciferase gene by T3 and T3
receptor in CV1 cells. Mol Cell Endocrinol 95: 101–9.
21. Maia AL, Kieffer JD, Harney JW, Larsen PR (1995) Effect of 3,5,39-
Triiodothyronine (T3) administration on dio1 gene expression and T3
metabolism in normal and type 1 deiodinase-deficient mice. Endocrinology
136: 4842–9.
22. Maia AL, Harney JW, Larsen PR (1996) Is there a negative TRE in the
luciferase reporter cDNA? Thyroid 6: 325–8.
23. Chan IH, Borowsky AD, Privalsky ML (2008) A cautionary note as to the use of
pBi-L and related luciferase/transgenic vectors in the study of thyroid
endocrinology. Thyroid 18: 665–6.
24. Boshart M, Kluppel M, Schmidt A, Schutz G, Luckow B (1992) Reporter
constructs with low background activity utilizing the cat gene. Gene 110:
129–30.
25. Park HY, Davidson D, Raaka BM, Samuels HH (1993) The herpes simplex
virus thymidine kinase gene promoter contains a novel thyroid hormone
response element. Mol Endocrinol 7: 319–30.
26. Nakano K, Matsushita A, Sasaki S, Misawa H, Nishiyama K, et al. (2004)
Thyroid-hormone-dependent negative regulation of thyrotropin b gene by
thyroid hormone receptors: study with a new experimental system using CV1
cells. Biochem J 378: 549–57.
27. Nagayama K, Sasaki S, Matsushita A, Ohba K, Iwaki H, et al. (2008) Inhibition
of GATA2-dependent transactivation of the TSHb gene by ligand-bound
estrogen receptor a. J Endocrinol 199: 113–25.
28. Jensen FC, Girardi AJ, Gilden RV, Koprowski H (1964) Infection Of Human
AndSimianTissueCultures WithRousSarcomaVirus.ProcNatlAcadSciUSA
52: 53–9.
29. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of
mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell
Biol 7: 379–87.
30. Sasaki S, Nakamura H, Tagami T, Miyoshi Y, Nakao K (1995) Functional
properties of a mutant T3 receptor b (R338W) identified in a subject with
pituitary resistance to thyroid hormone. Mol Cell Endocrinol 113: 109–17.
31. Kohler PO, Bridson WE (1971) Isolation of hormone-producing clonal lines of
human choriocarcinoma. J Clin Endocrinol Metab 32: 683–7.
32. Chatterjee VK, Lee JK, Rentoumis A, Jameson JL (1989) Negative regulation of
the thyroid-stimulating hormone a gene by thyroid hormone: receptor
interaction adjacent to the TATA box. Proc Natl Acad Sci U S A 86: 9114–8.
33. Kashiwabara Y, Sasaki S, Matsushita A, Nagayama K, Ohba K, et al. (2009)
Functions of PIT1 in GATA2-dependent transactivation of the thyrotropin b
promoter. J Mol Endocrinol 42: 225–37.
34. Umesono K, Murakami KK, Thompson CC, Evans RM (1991) Direct repeats
as selective response elements for the thyroid hormone, retinoic acid, and
vitamin D3 receptors. Cell 65: 1255–66.
35. Na ¨a ¨r AM, Boutin JM, Lipkin SM, Yu VC, Holloway JM, et al. (1991) The
orientation and spacing of core DNA-binding motifs dictate selective
transcriptional responses to three nuclear receptors. Cell 65: 1267–79.
36. Saatcioglu F, Deng T, Karin M (1993) A novel cis element mediating ligand-
independent activation by c-ErbA: implications for hormonal regulation. Cell
75: 1095–105.
37. Berghagen H, Ragnhildstveit E, Krogsrud K, Thuestad G, Apriletti J, et al.
(2002) Corepressor SMRT functions as a coactivator for thyroid hormone
receptor T3Ra from a negative hormone response element. J Biol Chem 277:
49517–22.
38. Nagaya T, Madison LD, Jameson JL (1992) Thyroid hormone receptor mutants
that cause resistance to thyroid hormone. Evidence for receptor competition for
DNA sequences in target genes. J Biol Chem 267: 13014–9.
39. Nagaya T, Jameson JL (1993) Thyroid hormone receptor dimerization is
required for dominant negative inhibition by mutations that cause thyroid
hormone resistance. J Biol Chem 268: 15766–71.
40. Madison LD, Ahlquist JA, Rogers SD, Jameson JL (1993) Negative regulation of
the glycoprotein hormone a gene promoter by thyroid hormone: mutagenesis of
a proximal receptor binding site preserves transcriptional repression. Mol Cell
Endocrinol 94: 129–36.
41. Yarwood NJ, Gurr JA, Sheppard MC, Franklyn JA (1993) Estradiol modulates
thyroid hormone regulation of the human glycoprotein hormone a subunit gene.
J Biol Chem 268: 21984–9.
42. Wondisford FE, Steinfelder HJ, Nations M, Radovick S (1993) AP-1 antagonizes
thyroid hormone receptor action on the thyrotropin b-subunit gene. J Biol Chem
268: 2749–54.
43. Cohen O, Flynn TR, Wondisford FE (1995) Ligand-dependent antagonism by
retinoid X receptors of inhibitory thyroid hormone response elements. J Biol
Chem 270: 13899–905.
44. Hollenberg AN, Monden T, Flynn TR, Boers ME, Cohen O, et al. (1995) The
human thyrotropin-releasing hormone gene is regulated by thyroid hormone
through two distinct classes of negative thyroid hormone response elements. Mol
Endocrinol 9: 540–50.
45. Kim SW, Hong SJ, Kim KM, Ho SC, So EC, et al. (2004) A novel cell type-
specific mechanism for thyroid hormone-dependent negative regulation of the
human type 1 deiodinase gene. Mol Endocrinol 18: 2924–36.
46. Brent GA, Larsen PR, Harney JW, Koenig RJ, Moore DD (1989) Functional
characterization of the rat growth hormone promoter elements required for
induction by thyroid hormone with and without a co-transfected b type thyroid
hormone receptor. J Biol Chem 264: 178–82.
47. Voz ML, Peers B, Wiedig MJ, Jacquemin P, Belayew A, et al. (1992)
Transcriptional regulation by triiodothyronine requires synergistic action of the
thyroid receptor with another trans-acting factor. Mol Cell Biol 12: 3991–7.
48. Zhuang Y, Butler B, Hawkins E, Paguio A, Orr L, et al. (2001) New Synthetic
Renilla Gene and Assay System Increase Expression, Reliability and Sensitivity.
Promega Notes 79: 6–11.
49. Sherf B (1994) Wood K 1994 Firefly Luciferase Engineered for Improved
Genetic Reporting. Promega Notes Magazine Number 49, (1994), p. 14 49:
14–21.
50. Liu YY, Brent GA (2008) Stealth sequences in reporter gene vectors confound
studies of T3-regulated negative gene expression. Thyroid 18: 593–5.
51. Paguio A, Almond B, Fan F, Stecha P, Garvin D, et al. (2005) pGL4 Vectors: A
New Generation of Luciferase Reporter Vectors. Promega Notes 89: 7–10.
52. Thompson JF, Hayes LS, Lloyd DB (1991) Modulation of firefly luciferase
stability and impact on studies of gene regulation. Gene 103: 171–7.
53. Naylor LH (1999) Reporter gene technology: the future looks bright. Biochem
Pharmacol 58: 749–57.
54. Pennathur S, Madison LD, Kay TW, Jameson JL (1993) Localization of
promoter sequences required for thyrotropin-releasing hormone and thyroid
hormone responsiveness of the glycoprotein hormone a-gene in primary cultures
of rat pituitary cells. Mol Endocrinol 7: 797–805.
55. Chin S, Apriletti J, Gick G (1998) Characterization of a negative thyroid
hormone response element in the rat sodium, potassium-adenosine triphospha-
tase a3 gene promoter. Endocrinology 139: 3423–31.
56. Wright CE, Haddad F, Qin AX, Bodell PW, Baldwin KM (1999) In vivo
regulation of b-MHC gene in rodent heart: role of T3 and evidence for an
upstream enhancer. Am J Physiol 276: C883–91.
57. Dupre SM, Guissouma H, Flamant F, Seugnet I, Scanlan TS, et al. (2004) Both
thyroid hormone receptor (TR) b 1 and TR b 2 isoforms contribute to the
regulation of hypothalamic thyrotropin-releasing hormone. Endocrinology 145:
2337–45.
58. Kim SW, Ho SC, Hong SJ, Kim KM, So EC, et al. (2005) A novel mechanism
of thyroid hormone-dependent negative regulation by thyroid hormone
receptor, nuclear receptor corepressor (NCoR), and GAGA-binding factor on
the rat cD44 promoter. J Biol Chem 280: 14545–55.
59. Santos GM, Afonso V, Barra GB, Togashi M, Webb P, et al. (2006) Negative
regulation of superoxide dismutase-1 promoter by thyroid hormone. Mol
Pharmacol 70: 793–800.
Luciferase Gene Mediates T3-Induced Inhibition
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e2891660. Newton AC (1995) Protein kinase C: structure, function, and regulation. J Biol
Chem 270: 28495–8.
61. Annicotte JS, Schoonjans K, Haby C, Auwerx J (2001) An E-box in pGL3
reporter vectors precludes their use for the study of sterol regulatory element-
binding proteins. Biotechniques 31: 993–4, 996.
62. Osborne SA, Tonissen KF (2002) pRL-TK induction can cause misinterpre-
tation of gene promoter activity. Biotechniques 33: 1240–2.
63. Ho CK, Strauss JF, 3rd (2004) Activation of the control reporter plasmids pRL-
TK and pRL-SV40 by multiple GATA transcription factors can lead to aberrant
normalization of transfection efficiency. BMC Biotechnol 4: 10.
64. Gothe S, Wang Z, Ng L, Kindblom JM, Barros AC, et al. (1999) Mice devoid of
all known thyroid hormone receptors are viable but exhibit disorders of the
pituitary-thyroid axis, growth, and bone maturation. Genes Dev 13: 1329–41.
65. Calza L, Forrest D, Vennstrom B, Hokfelt T (2000) Expression of peptides and
other neurochemical markers in hypothalamus and olfactory bulb of mice
devoid of all known thyroid hormone receptors. Neuroscience 101: 1001–12.
66. Abel ED, Ahima RS, Boers ME, Elmquist JK, Wondisford FE (2001) Critical
role for thyroid hormone receptor b 2 in the regulation of paraventricular
thyrotropin-releasing hormone neurons. J Clin Invest 107: 1017–23.
67. Mansen A, Yu F, Forrest D, Larsson L, Vennstrom B (2001) TRs have common
and isoform-specific functions in regulation of the cardiac myosin heavy chain
genes. Mol Endocrinol 15: 2106–14.
68. Feng X, Jiang Y, Meltzer P, Yen PM (2000) Thyroid hormone regulation of
hepatic genes in vivo detected by complementary DNA microarray. Mol
Endocrinol 14: 947–55.
69. Luckow B, Schutz G (1987) CAT constructions with multiple unique restriction
sites for the functional analysis of eukaryotic promoters and regulatory elements.
Nucleic Acids Res 15: 5490.
70. Nakabeppu Y, Ryder K, Nathans D (1988) DNA binding activities of three
murine Jun proteins: stimulation by Fos. Cell 55: 907–15.
Luciferase Gene Mediates T3-Induced Inhibition
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e28916